The impact of graft-versus-host disease in the development of oral cancer after allogeneic hematopoietic stem cell transplantation: report of 2 cases

Graziella Chagas Jaguar†, Luiz Paulo Kowalski†, Danyel Elias da Cruz Perez†, Clovis Antonio Lopes Pinto†, Carina Magalhães Esteves† and Fabio Abreu Alves†

†All authors contributed equally to this work.

1Stomatology Department – Cancer Hospital A.C Camargo, São Paulo, Brazil.
2Head and Neck Department- Cancer Hospital A.C Camargo, São Paulo, Brazil.
3Pathology Department- Pernambuco Federal University, Recife, Brazil.
4Pathology Department- Cancer Hospital A.C Camargo, São Paulo, Brazil.
5Pathology Department- São Paulo University, São Paulo, Brazil.

Abstract

Background: The development of oral cancer following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rare and its etiology is controversial. Oral graft-versus-host disease (GVHD) has been described as a possible risk factor for this condition.

Methods and Results: The authors report 2 cases of oral squamous cell carcinoma developed 13 and 15 years after allo-HSCT, respectively. Both patients had no history of smoking or alcohol consumption and the tumor developed in the same area previously affected by oral chronic GVHD. Treatment consisted of surgery and adjuvant radiotherapy in one patient and radiotherapy associated to targettherapy in the other one. The patients are alive and no recurrence was detected after 24 and 22 months of follow-up.

Conclusions: This article showed that oral chronic GVHD following allo-HSCT seem to be a potential risk factor in the development of oral carcinoma and emphasized the importance of long term follow-up periods for hematological transplanted patients.

Keywords: Allogeneic hematopoietic stem cell transplantation (allo-HSCT), graft-versus-host disease (GVHD), secondary cancer, oral squamous cell carcinoma

Introduction

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the standard treatment of various hematologic malignancies, as well as hematologic and metabolic disorders, with successful results in survival rates [1,2]. This procedure, however, is frequently associated with a wide range of complications, being graft-versus-host disease (GVHD) one of the most important and disabling effect with important impact in patients’ quality of life [3].

Previous studies suggest that GVHD may increase the risk for the developing of secondary solid neoplasms, particularly squamous cell carcinoma [2,4,5]. This correlation is controversial in the literature. Some authors state that the occurrence of new secondary malignancies may be attributed to several factors such as cumulative toxicity of previous chemotherapy or radiotherapy, conditioning regimes, immunosuppressive GVHD prophylaxis, viral infections, antigenic differences between recipient and donor, gender and age [6,7,8,9,10]. On the other hand, the incidence of solid tumors, especially oral squamous cell carcinoma, seems to be higher in patients who developed previous oral GVHD at the same anatomic area [3,4,5].

The exact etiology for this process is still obscure [3]. It has been suggested that the long-term immunologic injury of the mucosa by chronic GVHD inflammatory process may predispose this tissue to malignant transformation [7,8]. The aim of this report was to describe the clinical presentation of two patients who developed oral squamous cell carcinoma 13 and 15 years post allo-HSCT, respectively, in the same area previously affected by oral GVHD.

Case 1

A 50-year-old woman was referred to the Stomatology Department, Hospital AC Camargo, São Paulo, Brazil, for evaluation of symptomatic lesion involving inferior lip with 1 month duration. The patient denied tobacco and alcohol consumption. On history, the patient revealed allo-HSCT 13 years ago due to multiple myeloma. The conditioning regimen transplant included Busulphan (1mg\(\text{Kg}\)\text{dose} for 4 days), cyclophosphamide (45mg\(\text{Kg}\)\text{dose} for 2 days) and Melphalan (100mg\(\text{m}\)2 for 1 day). Prophylaxis against GVHD consisted of cyclosporine A (1,5mg\(\text{Kg}\)\text{dose}) and methotrexate (29mg\(\text{Kg}\)\text{dose} for 4 days: D+1, D+3, D+6 and D+11). According to the hospital records, at day 176 after allo-HSCT, the patient developed bilateral white lichenoid-type lesions on the buccal mucosa and inferior lip (Figure 1). Clinical and histopathological features confirmed oral chronic GVHD. At that time, no topical therapy was carried out.

During our present clinical evaluation, it was noted an
lesion in the tongue with 8 months of duration. Patient denied tobacco and alcohol consumption. General medical history revealed an allo-HSCT 15 years ago for acute leukaemia treatment. Conditioning regimen transplant include Busulphan (1mg\Kg\dose for 4 days: D-7, D-6, D-5 and D-4) and cyclophosphamide (120 mg\Kg\dose for 2 days: D-3 and D-2). GVHD prophylaxis consisted of methotrexate (19mg\Kg\dose for 3 days). At day 158 after allo-HSCT, the patient presented multiple red and white lichenoid erosive lesions affecting tongue, hard palate and inferior lip mucosa (Figure 3A-B). Both clinical and histopathological features confirmed oral chronic GVHD. Patient was treated with methotrexate during 6 months.

On clinical evaluation, the patient had a painless indurated mass with necrotic surface and indurate borders involving inferior lip (Figure 2). The main diagnosis hypothesis was squamous cell carcinoma. The incisional biopsy confirmed oral squamous cell carcinoma and the tumor was staged as T3N1MO. Treatment consisted of surgery and adjuvant radiotherapy. Patient has no evidence of disease after two years of follow-up.

Case 2
A 24 year-old woman was referred due to a symptomatic lesion in the tongue with 8 months of duration. Patient denied tobacco and alcohol consumption. General medical history revealed an allo-HSCT 15 years ago for acute leukaemia treatment. Conditioning regimen transplant include Busulphan (1mg\Kg\dose for 4 days: D-7, D-6, D-5 and D-4) and cyclophosphamide (120 mg\Kg\dose for 2 days: D-3 and D-2). GVHD prophylaxis consisted of methotrexate (19mg\Kg\dose for 3 days). At day 158 after allo-HSCT, the patient presented multiple red and white lichenoid erosive lesions affecting tongue, hard palate and inferior lip mucosa (Figure 3A-B). Both clinical and histopathological features confirmed oral chronic GVHD. Patient was treated with methotrexate during 6 months.

On clinical evaluation, the patient had a painless indurated mass with necrotic surface measured about 6 cm involving entire right border of the oral tongue extending to the oropharynx (Figure 4). Again, squamous cell carcinoma was the clinical diagnoses and it was confirmed by incisional biopsy. The clinical stage was T4N0M0. Tumor resection was not indicated due to patient’s unfavorable clinical conditions. Consequently, radiotherapy and chemotherapy (cetuximab)
was indicated. After 22 months of treatment, no recurrence was detected.

Discussion

The development of secondary malignancies has been considered the major cause of morbidity after allo-HSCT with significant impact on late mortality [10]. The most common secondary malignancies include haematological disease such as leukaemia, Hodgkin’s disease, non-Hodgkin’s lymphoma and granulocytic sarcoma, which frequently occur in the early period post transplant [1,8]. Although rare, secondary solid tumors, especially squamous cell carcinoma in the skin and in the oral cavity, have been reported in the literature [4,5,11-13].

Different to secondary hematological malignancies, the incidence of solid tumor increases with time: 0.4% in the first 5 years post-transplant, 3.5% in 10 years and 12.8% in 15 years [8]. In addition, it is reported that the risk increases its peak between 8 and 9 years after allo-HSCT, in patients who are 10-29 years old at the time of transplantation while it decreases in those who are older than 30 years [1]. The present cases differ from these studies reported in the literature. Our two patients developed oral squamous cell carcinomas approximately 13 and 15 years after allo-HSCT, respectively. In addition, one patient (case 1) was older than 30 years at the time of transplantation.

The occurrence of oral carcinoma after allo-HSCT has been attributed to several risk factors. Known risk factors for the general population, such as smoking, alcohol consumption and older age are not relevant in these patients [3,11]. Oral GVHD, a chronic mucosal inflammation, has been suspected to be a potential risk factor for the development of squamous cell cancers of the oral cavity [2-5,11,13-14]. Both of our patients had no history of smoking or alcohol consumption and oral squamous cell carcinoma developed in the same area previously affected by oral GVHD.

GVHD is a frequent complication after allo-HSCT caused by a immunologic reaction from grafting immunocompetent cells to an immunodeficient host [15]. Chronic GVHD occurs in approximately 60–80% of long-term patients [16] and most often affects the skin, liver, gastrointestinal tract, lungs and eyes [11,15]. Oral GVHD occurs in approximately 60-80% of patients with clinical manifestations of atrophy, erythema, lichenoid lesions, xerostomia and oral pain with important impact on eating, drinking and oral hygiene procedures [15]. Clinically, in our patients the carcinoma arose in the oral mucosa that previously had shown hyperkeratotic striae, atrophy, ulceration and pain with clinical and histological diagnosis of oral GVHD. These observations may suggest that chronic GVHD is a strong risk factor for the development of oral squamous cell carcinoma.

The exact mechanism for the malignant transformation of oral GVHD is still unknown. Some authors believe that oral GVHD is histologically identical to oral lichen planus, which it is considered a significant malignant potential lesion [3,5]. In addition, both diseases have the same pathogenesis involving T-lymphocytes that chronically attack the oral epithelium. In agreement to the literature, in our opinion, one of the main aspects to malignant transformation is the long-term immunologic damage to the mucosa by T-cells. The time between the diagnosis of oral GVHD and carcinoma ranged from 2 to more than 10 years [14]. The presence of dysplastic alterations in the oral mucosa before carcinoma onset is not reported in the literature. In the present series, carcinoma was diagnosed 13 (patient 1) and 15 years (patient 2) after oral GVHD diagnosis and no dysplastic alterations were presented in GVHD lesions. Further studies focusing on identifying early clinical and pathological alterations aiming to early diagnose of cancer could significantly improve survival related patient’s quality of life.

Conclusion

This article showed that oral GVHD following allo-HSCT seem to be a potential risk factor in the development of oral carcinoma even a very long time after transplant. Due to that, we emphasized the importance of long follow-up periods for these patients and to biopsy any suspicious lesions.

Competing interests

The authors declare that they have no competing interests.

Publication history

Received: 18-Feb-2013 Revised: 30-Apr-2013 Accepted: 16-May-2013 Published: 04-Jun-2013

References


Citation: